Research & development
Isofol is developing the drug candidate arfolitixorin with the aim of increasing the efficacy of current standard treatments for colorectal cancer*, the third most common form of cancer in the world, and certain other tumor diseases.
Today, there is a very high need for a more effective baseline treatment of metastatic colorectal cancer (mCRC). The number of people affected increases every year. The global incidence (the number of new patients who are diagnosed with this form of cancer annually) was just over 1,9 million patients a year in 2022, while about 0.9 million died from the disease that year1. Arfolitixorin is currently being evaluated with the aim to contribute to the baseline treatment of colorectal cancer in the future.
Isofol currently has no drugs on the market.
* Colorectal cancer, also known as intestinal or rectal cancer, is a form of cancer that arises from uncontrolled cell growth in the large intestine, rectum or appendix.
Sources: 1) Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today (version 1.1). Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.who.int/today, accessed [27 March 2024].
Last updated 05-15-2024
